PL205733B1 - Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie - Google Patents

Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie

Info

Publication number
PL205733B1
PL205733B1 PL374510A PL37451002A PL205733B1 PL 205733 B1 PL205733 B1 PL 205733B1 PL 374510 A PL374510 A PL 374510A PL 37451002 A PL37451002 A PL 37451002A PL 205733 B1 PL205733 B1 PL 205733B1
Authority
PL
Poland
Prior art keywords
mmol
preparation
added
benzopyran
dihydro
Prior art date
Application number
PL374510A
Other languages
English (en)
Polish (pl)
Other versions
PL374510A1 (en
Inventor
Jeffrey Alan Dodge
Venkatesh Gary Krishnan
Charles Willis Lugar Iii
Blake Lee Neubauer
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL374510A1 publication Critical patent/PL374510A1/xx
Publication of PL205733B1 publication Critical patent/PL205733B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
PL374510A 2001-11-19 2002-11-07 Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie PL205733B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11

Publications (2)

Publication Number Publication Date
PL374510A1 PL374510A1 (en) 2005-10-31
PL205733B1 true PL205733B1 (pl) 2010-05-31

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374510A PL205733B1 (pl) 2001-11-19 2002-11-07 Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie

Country Status (23)

Country Link
US (1) US7217734B2 (enExample)
EP (1) EP1448544B1 (enExample)
JP (1) JP4381810B2 (enExample)
KR (1) KR100950616B1 (enExample)
CN (1) CN1312147C (enExample)
AT (1) ATE362471T1 (enExample)
AU (1) AU2002359283B2 (enExample)
CA (1) CA2467013C (enExample)
CY (1) CY1106726T1 (enExample)
DE (1) DE60220179T2 (enExample)
DK (1) DK1448544T3 (enExample)
EA (1) EA007382B1 (enExample)
EC (1) ECSP045113A (enExample)
ES (1) ES2286322T3 (enExample)
HR (1) HRP20040439A2 (enExample)
HU (1) HU229351B1 (enExample)
IL (3) IL161325A0 (enExample)
MX (1) MXPA04004703A (enExample)
NO (1) NO328563B1 (enExample)
NZ (1) NZ531850A (enExample)
PL (1) PL205733B1 (enExample)
PT (1) PT1448544E (enExample)
WO (1) WO2003044006A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1626974B1 (en) * 2003-04-21 2008-08-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
ATE504582T1 (de) * 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
US20060166933A1 (en) * 2004-11-18 2006-07-27 Jain Nareshkumar F Novel 2H-chromene derivatives as selective estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
CN105960236A (zh) 2013-12-05 2016-09-21 卡罗医药股份公司 用于治疗间皮瘤的雌激素受体β激动剂
JP6978420B2 (ja) 2015-09-17 2021-12-08 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法
WO2021183760A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
EP0935000A3 (en) 1995-09-08 1999-09-08 Karo Bio Ab Orphan receptor
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
TR200102992T2 (tr) 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
CA2396059A1 (en) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7214706B2 (en) * 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
ES2293986T3 (es) 2000-03-27 2008-04-01 N.V. Organon Compuestos no esteroides tetraciclicos para tratamientos relacionados con el estrogeno.
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
NO20042583L (no) 2004-06-18
NO328563B1 (no) 2010-03-22
KR20040063963A (ko) 2004-07-15
US7217734B2 (en) 2007-05-15
HK1068349A1 (en) 2005-04-29
AU2002359283B2 (en) 2007-06-21
MXPA04004703A (es) 2004-08-19
PL374510A1 (en) 2005-10-31
JP4381810B2 (ja) 2009-12-09
DE60220179D1 (de) 2007-06-28
ES2286322T3 (es) 2007-12-01
IL161325A (en) 2008-07-08
IL161325A0 (en) 2004-09-27
HRP20040439A2 (en) 2005-04-30
CN1589268A (zh) 2005-03-02
US20040249167A1 (en) 2004-12-09
EA200400695A1 (ru) 2004-12-30
CY1106726T1 (el) 2012-05-23
IL185867A0 (en) 2008-01-06
KR100950616B1 (ko) 2010-04-01
EP1448544B1 (en) 2007-05-16
AU2002359283A1 (en) 2003-06-10
JP2005513027A (ja) 2005-05-12
NZ531850A (en) 2007-01-26
PT1448544E (pt) 2007-08-10
CN1312147C (zh) 2007-04-25
HUP0402628A2 (hu) 2005-04-28
HU229351B1 (en) 2013-11-28
EA007382B1 (ru) 2006-10-27
ECSP045113A (es) 2004-07-23
EP1448544A1 (en) 2004-08-25
CA2467013C (en) 2010-08-10
ATE362471T1 (de) 2007-06-15
CA2467013A1 (en) 2003-05-30
IL185867A (en) 2009-09-22
DE60220179T2 (de) 2008-02-07
WO2003044006A1 (en) 2003-05-30
DK1448544T3 (da) 2007-10-08
AU2002359283B8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
KR100487647B1 (ko) 벤조피란함유화합물및이들의사용방법
EP1618102B1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
IL185867A (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US20090298925A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US7671045B2 (en) 17-phosphorous steroid derivatives useful as progesterone receptor modulators
US7678781B2 (en) 11-phosphorous steroid derivatives useful as progesterone receptor modulators
US7354951B2 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US6630508B1 (en) Substituted benzopyrans as selective estrogen receptor β agonists
US6599921B2 (en) Non-steroidal estrogen receptor ligands
EP1790644A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
HK1068349B (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2003074044A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
ZA200403733B (en) Substituted benzopyrans as selective estrogen receptorbeta agonists.
UA77986C2 (en) Substituted benzopyran derivatives as selective estrogen beta-receptor agonists

Legal Events

Date Code Title Description
RECP Rectifications of patent specification